HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peripheral T-cell lymphoma in HIV-infected patients: a study of 17 cases in the combination antiretroviral therapy era.

Abstract
Most cases of human immunodeficiency virus (HIV)-associated non-Hodgkin Lymphoma (NHL) are of B-cell origin; T-cell NHLs are rarely reported. Within a single centre prospective cohort of 370 HIV-NHL, 17 (5%) were of T-cell origin (82% male; median age, 39 years). Median CD4+ cell count was 0·194 × 10(9) /l and 41% had undetectable plasma HIV-RNA at lymphoma diagnosis. All patients received combination antiretroviral therapy during chemotherapy. All histological samples were centrally reviewed. The distribution of the histological subtypes differed from the general population with absence of angioimmunoblastic subtype. Lymphoma was disseminated in 14 patients, and seven patients had performance status >2. All patients received full-dose chemotherapy: eight standard and nine intensive regimens. Two patients who received intensive chemotherapy died during therapy. The complete remission rate was 53%; 62·5% with standard therapy and 44% with intensive therapy. After a median follow-up of 7·2 years, the median overall survival was 9·4 months. Most deaths (85%) occurred within the first year following diagnosis, as a consequence of lymphoma progression in 10/13 cases. In this rare but severe complication of HIV infection the use of intensive chemotherapy does not appear to be beneficial for response, with increased toxicity.
AuthorsLaurent Gilardin, Christiane Copie-Bergman, Lionel Galicier, Véronique Meignin, Josette Brière, Julie F Timsit, Olivier Bouchaud, Philippe Gaulard, Eric Oksenhendler, Laurence Gérard
JournalBritish journal of haematology (Br J Haematol) Vol. 161 Issue 6 Pg. 843-51 (Jun 2013) ISSN: 1365-2141 [Electronic] England
PMID23593987 (Publication Type: Journal Article)
Copyright© 2013 John Wiley & Sons Ltd.
Topics
  • Adult
  • Algorithms
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Antiretroviral Therapy, Highly Active
  • Female
  • HIV Infections (complications, drug therapy)
  • Humans
  • Lymphoma, AIDS-Related (diagnosis, drug therapy, mortality)
  • Lymphoma, B-Cell (diagnosis, etiology)
  • Lymphoma, T-Cell, Peripheral (diagnosis, drug therapy, etiology, mortality)
  • Male
  • Middle Aged
  • Prognosis
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: